Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

INTRODUCTION: There are little data on the clinical activity of temsirolimus (TM) and everolimus (EV) when used as second-line therapy after sunitinib (SU) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Patients with mRCC treated with EV or TM after SU were included in this retros...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Iacovelli, Roberto, Cartenì, Giacomo, Milella, Michele, Berardi, Rossana, Di Lorenzo, Giuseppe, Verzoni, Elena, Rizzo, Mimma, Santoni, Matteo, Procopio, Giuseppe
Format: Artigo
Jezik:Inglês
Izdano: Canadian Medical Association 2014
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956829/
https://ncbi.nlm.nih.gov/pubmed/24678349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.1604
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki